Eugene A. Podrez

Eugene A. Podrez

Auto-generated profile, based on publicly available information

Eugene A. Podrez

Lerner Res Inst, Dept Inflammat & Immun, Cleveland Clin, Cleveland, OH 44195 USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2007 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
EPEugene A Podrez
Eugene A Podrez
Tatiana V. ByzovaTatiana V. Byzova
Tatiana V. Byzova
MFMaria Febbraio
Maria Febbraio
RSRobert Salomon
Robert Salomon
YMYi Ma
Yi Ma
SHStanley L Hazen
Stanley L Hazen

4 January 2013 in Circulation Research
Verified
Journal Article
Closed access
PDF file
SPSoumya Panigrahi
Soumya Panigrahi
YMYi Ma
Yi Ma
LHLi Hong
Li Hong
DGDetao Gao
Detao Gao
XWXiaoxia Z. West
Xiaoxia Z. West
EPEugene A. Podrez
Eugene A. Podrez
Rationale:: A prothrombotic state and increased platelet reactivity are common in pathophysiological conditions associated with oxidative stress and infections. Such conditions are associated with an appearance of altered-self ligands in circulation that can be recognized by Toll-like receptors (TLRs). Platelets express a number of TLRs, including TLR9; however, the role of TLR in platelet function and thrombosis is poorly understood. Objective:: To investigate the biological activities of carboxy(alkylpyrrole) protein adducts, an altered-self ligand generated in oxidative stress, on platelet function and thrombosis. Methods and Results:: In this study we show that carboxy(alkylpyrrole) protein adducts represent novel unconventional ligands for TLR9. Furthermore, using human and murine platelets, we demonstrate that carboxy(alkylpyrrole) protein adducts promote platelet activation, granule secretion, and aggregation in vitro and thrombosis in vivo via the TLR9/MyD88 pathway. Platelet activation by TLR9 ligands induces IRAK1 and AKT phosphorylation, and it is Src kinase—dependent. Physiological platelet agonists act synergistically with TLR9 ligands by inducing TLR9 expression on the platelet surface. Conclusions:: Our study demonstrates that platelet TLR9 is a functional platelet receptor that links oxidative stress, innate immunity, and thrombosis.

17 June 2010 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
EPEugene A Podrez
Eugene A Podrez

1 March 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
NKNiladri S. Kar
Niladri S. Kar
MAMohammad Z. Ashraf
Mohammad Z. Ashraf
MVManojkumar Valiyaveettil
Manojkumar Valiyaveettil
EPEugene A. Podrez
Eugene A. Podrez
Recent studies have identified a novel family of oxidized phosphatidylcholines (oxPCCD36) that serve as highly specific ligands for scavenger receptor CD36. oxPCCD36 accumulate in vivo and mediate macrophage foam cell formation as well as promote platelet hyper-reactivity in hyperlipidemia via CD36. The structural basis of oxPCCD36 binding to CD36 has not been elucidated. We used liquid-phase binding to glutathione S-transferase fusion proteins containing various regions of CD36 to initially identify the region spanning CD36 amino acids 157-171 to contain a major binding site for oxPCCD36. A bell-shaped pH profile and salt concentration dependence suggest an electrostatic mechanism of the binding. Two conserved, positively charged amino acids in the region 157-171 (lysines at positions 164 and 166) were identified as critical for oxPCCD36 and oxidized low density lipoprotein (oxLDL) binding to CD36. Lysine neutralization with chemical modifier or site-directed mutagenesis of lysine 164/166 to alanine or glutamate, but not to arginine, abolished binding. Cells expressing full-length CD36 with mutated lysines (164 and 166) failed to recognize oxPCCD36 and oxLDL. Synthetic peptides mimicking the CD36 binding site, but not mutated or scrambled peptides, effectively prevented: (i) oxLDL binding to CD36, (ii) macrophage foam cell formation induced by oxLDL, and (iii) platelet activation by oxPCCD36. These data indicate that CD36 (160-168) represents the core of the oxPCCD36 binding site with lysines 164/166 being indispensable for the binding.

26 May 2023 in Circulation Research
Verified
Journal Article
Closed access
TDTejasvi Dudiki
Tejasvi Dudiki
MVManoj Veleeparambil
Manoj Veleeparambil
IZIrina Zhevlakova
Irina Zhevlakova
SBSudipta Biswas
Sudipta Biswas
EKEric A. Klein
Eric A. Klein
Tatiana V. ByzovaTatiana V. Byzova
Tatiana V. Byzova
Background: Thrombosis is one of the main complications in cancer patients often leading to mortality. However, the mechanisms underlying platelet hyperactivation are poorly understood. Methods: Murine and human platelets were isolated and treated with small extracellular vesicles (sEVs) from various cancer cell lines. The effects of these cancer-sEVs on platelets were evaluated both in vitro and in vivo using various approaches, including the detection of cancer-sEV-specific markers in murine platelets and patient samples, measurement of platelet activation and thrombosis assays. Signaling events induced by cancer-sEVs and leading to platelet activation were identified, and the use of blocking antibodies to prevent thrombosis was demonstrated. Results: We demonstrate that platelets very effectively take up sEVs from aggressive cancer cells. The process of uptake is fast, proceeds effectively in circulation in mice, and is mediated by the abundant sEV membrane protein-CD63. The uptake of cancer-sEVs leads to the accumulation of cancer cell-specific RNA in platelets in vitro and in vivo. The human prostate cancer-sEV-specific RNA marker PCA3 is detected in platelets of ~70% of prostate cancer patients. This was markedly reduced after prostatectomy. In vitro studies showed that platelet uptake of cancer-sEVs induces strong platelet activation in a CD63-RPTPα (receptor-like protein tyrosine phosphatase alpha)-dependent manner. In contrast to physiological agonists ADP and thrombin, cancer-sEVs activate platelets via a noncanonical mechanism. Intravital studies demonstrated accelerated thrombosis both in murine tumor models and in mice that received intravenous injections of cancer-sEVs. The prothrombotic effects of cancer-sEVs were rescued by blocking CD63. Conclusions: Tumors communicate with platelets by means of sEVs, which deliver cancer markers and activate platelets in a CD63-dependent manner leading to thrombosis. This emphasizes the diagnostic and prognostic value of platelet-associated cancer markers and identifies new pathways for intervention.

1 June 2012 in Cell Metabolism
Verified
Journal Article
Closed access
LDLiang Ding
Liang Ding
SBSudipta Biswas
Sudipta Biswas
RMRichard E. Morton
Richard E. Morton
JSJonathan D Smith
Jonathan D Smith
NHNissim Hay
Nissim Hay
EPEugene A. Podrez
Eugene A. Podrez